Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca, Sage Bionetworks Partner on Cancer Therapeutic Development

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Sage Bionetworks today announced a deal with AstraZeneca aimed at the personalized treatment of cancer patients.

The deal, Sage said, may also lead to the development of new cancer therapeutics.

Sage will combine its expertise in computer models of disease genetics with AstraZeneca's expertise in oncology as well as access to the drug manufacturer's compounds to investigate regulatory pathways common in different cancers. The work will use large coherent cancer genomic datasets and predictive disease models developed by Sage.

Financial and other terms of the deal were not disclosed.

The collaboration, Sage said, could potentially provide data-driven rationales for prioritizing therapeutic targets for new drug development and help identify patients who may benefit the most from such new drugs.

"We are looking forward to collaborating with Sage Bionetworks to build realistic, predictive models of cancers to expand our current understanding of these diseases and potentially harness that knowledge into new target identification, portfolio positioning, and patient selection, all of which we hope will lead to new treatment options for patients," Susan Galbraith, vice president and head of the Oncology Innovative Medicines unit at AstraZeneca, said in a statement.

Based in Seattle, Sage is a non-profit medical research organization that uses molecular and clinical datasets for improved therapeutic development.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.